LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

First-of-Its-Kind Mobile Testing Platform Launched to Manage and Track On-Site COVID-19 Testing

By LabMedica International staff writers
Posted on 28 Aug 2020
Print article
Image: Fionet’s workflow (Photo courtesy of Fio Corporation)
Image: Fionet’s workflow (Photo courtesy of Fio Corporation)
A new first-of-its-kind COVID-19 mobile testing and tracking platform aims to enable lab-grade diagnostic testing in clinics, pharmacies, workplaces, airports, nursing homes and other community-based locations.

The new COVID-19 testing, data collection and reporting solution, Fionet, has been developed jointly by Relay Medical Corp. (Toronto, Canada) and Fio Corporation (Toronto, Canada). The Fionet mobile testing and tracking platform has been specifically developed for controlled, rapid response to pandemics. The platform combines handheld devices linked to online AI-powered cloud, automating frontline testing and capturing test results for tracking. Fionet’s rugged, mobile devices are compatible with multiple third-party antigen and antibody COVID-19 rapid diagnostic tests (RDTs), which creates sourcing flexibility for RDTs that are of limited supply and continuously evolving. Fionet also connects with molecular testing devices such as PCRs.

Flexible and customizable, Fionet enables testing to be expanded beyond the few overburdened medical centers to small clinics, pharmacies, workplaces, airports, nursing homes, schools, etc. and performed at hospital-grade accuracy, in higher volume, faster-speed, and by less-skilled frontline workers. Fionet has a proven, positive impact on one million patients with infectious diseases in over a dozen countries and four continents.

“Community-based testing and real-time tracking is indispensable for combating pandemics like COVID-19. Fionet has already made this happen in the most challenging epidemic regions on the planet and we are now preparing for imminent deployment of our platform with several partners to combat COVID-19 at home and abroad,” said Dr Michael Greenberg, CEO of Fionet Rapid Response Group, a joint venture set up by Relay Medical and Fio Corp.

“The many transformational benefits delivered by Fionet have been validated and documented in several dozen scientific and medical journals. Fionet has successfully reduced testing errors by 23%, achieves 99.5%1 diagnostic accuracy rate compared to expert lab techs, and provides significant economic efficiencies,” said Yoav Raiter, CEO, Relay Medical Corp.

Related Links:
Relay Medical Corp.
Fio Corporation


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 RT-PCR Assay
Reliance SARS-CoV-2 RT-PCR Assay Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more